Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America

NEW YORK., April 3, 2023 – Sumitovant Biopharma Ltd. (“Sumitovant”) announced today that its parent  company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”) will combine its wholly owned U.S.  subsidiaries to form Sumitomo Pharma America, Inc. (“Sumitomo Pharma America”). Sumitomo Pharma  America will combine Sumitovant and its wholly owned U.S. subsidiaries, Myovant Sciences, Inc.,  Urovant Sciences, Inc., and Enzyvant Therapeutics, Inc., as well as Sumitomo Pharma’s other U.S.  subsidiaries Sumitomo Pharma America Holdings, Inc., Sumitomo Pharma Oncology, Inc., and Sunovion Pharmaceuticals Inc. Spirovant Sciences, Inc., Sumitovant’s remaining wholly owned subsidiary, will  operate as a standalone company under Sumitomo Pharma America.  

Sumitovant’s current CEO Myrtle Potter will serve as President and CEO of Sumitomo Pharma America  upon completion of the combination July 1, 2023. 

Sumitomo Pharma America will establish a science-based, technology-driven biopharmaceutical  company focused on addressing unmet patient needs in the critical areas of central nervous system,  oncology, urology, women’s health, and cell and gene therapies. Sumitomo Pharma America will house a  diverse portfolio of commercialized products and robust pipeline of early- to late-stage assets leveraging  proprietary technology platforms and advanced computational analytics capabilities to accelerate  research, development, and potential commercialization of new therapies. Each subsidiary will continue  to operate independently until the combination is complete but are collaborating on key integration  efforts in the interim to allow for a smooth transition for all stakeholders in preparation for Day 1 of  Sumitomo Pharma America. 

Hiroshi Nomura, President and CEO of Sumitomo Pharma, said, “We remain deeply committed to  addressing pressing health challenges and believe Sumitomo Pharma America will serve as a valuable  growth engine. Sumitomo Pharma America will have increased scale and a combined network of  resources and talent to accelerate a diverse portfolio of commercial and investigational programs for  critical indications while creating a sustainable platform for growth.”  

“This important combination was made possible by the incredible work being done across Sumitovant  and its subsidiaries Myovant, Urovant, Enzyvant and Spirovant. We look forward to bringing together  our strengths with Sumitomo Pharma’s other U.S. subsidiaries to create an innovative biopharma  company with the scale, agility and efficiency needed for accelerated impact and patient-focused  outcomes,” said Myrtle Potter, current CEO of Sumitovant and future President and CEO of Sumitomo  Pharma America. “We will combine our deep R&D and life sciences expertise with unparalleled advance  technology platforms, DrugOME and Digital Innovation, to underpin growth of existing product lines and  pipeline efforts. Sumitomo Pharma America will build on the group’s mission and bring needed  therapies to patients sooner in key areas where treatment options remain limited or non-existent.” 


About Sumitovant Biopharma Ltd. 

Sumitovant is a technology-driven biopharmaceutical company accelerating development and  commercialization of new potential therapies for patients with rare conditions and other diseases. 

Through its proprietary computing and data platforms, scientific expertise and diverse company  portfolio, Sumitovant has supported development of multiple FDA-approved products and a robust  pipeline of early- through late-stage investigational assets addressing unmet patient needs in pediatrics,  urology, oncology, women’s health, specialty respiratory and infectious diseases. Sumitovant Biopharma  is a wholly owned subsidiary of Sumitomo Pharma. Please visit our website for  more information on Sumitovant and our portfolio. 

About Myovant Sciences 

Myovant Sciences aspires to redefine care for women and men through purpose-driven science,  empowering medicines, and transformative advocacy worldwide. Since its formation in 2016, Myovant  has secured five regulatory approvals in the United States and Europe for its products ORGOVYX® and  MYFEMBREE® in hormone-sensitive oncology and women’s health, respectively. Myovant and its  partners continue to file for additional indications of its products, as well as advance development of its  pipeline. Myovant is a wholly owned subsidiary of Sumitovant Biopharma Ltd., as of March 10, 2023. For  more information, please visit

About Urovant Sciences 

Urovant Sciences is a biopharmaceutical company focused on developing and commercializing  innovative therapies for areas of unmet need, with a dedicated focus in urology. The Company’s lead  product, GEMTESA® (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist for the  treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence,  urgency, and urinary frequency. GEMTESA was approved by the U.S. FDA in December 2020 and  launched in the U.S. in April 2021. Urovant Sciences, a wholly owned subsidiary of Sumitovant  Biopharma Ltd., intends to bring innovation to patients in need in urology and other areas of unmet  need. Named one of the Fortune® Best Workplaces in BioPharma™ (2022), twice as one of the “Best  Places to Work” in Orange County by the Orange County Business Journal (2021, 2022) and winner of  the PM360 Trailblazer Award for Best Product Launch of the Year, Urovant’s people-focused culture  leads the way for innovation and impact. Learn more at  


GEMTESA® (vibegron) is a prescription medicine for adults used to treat the following symptoms due to  a condition called overactive bladder: 

  • urge urinary incontinence: a strong need to urinate with leaking or wetting accidents
  • urgency: the need to urinate right away 
  • frequency: urinating often 

It is not known if GEMTESA is safe and effective in children. 


Do not take GEMTESA if you are allergic to vibegron or any of the ingredients in GEMTESA. 

Before you take GEMTESA, tell your doctor about all your medical conditions, including if you have  liver problems; have kidney problems; have trouble emptying your bladder or you have a weak urine  stream; take medicines that contain digoxin; are pregnant or plan to become pregnant (it is not known if 

GEMTESA will harm your unborn baby; talk to your doctor if you are pregnant or plan to become  pregnant); are breastfeeding or plan to breastfeed (it is not known if GEMTESA passes into your breast  milk; talk to your doctor about the best way to feed your baby if you take GEMTESA). 

Tell your doctor about all the medicines you take, including prescription and over-the-counter  medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show  your doctor and pharmacist when you get a new medicine. 

What are the possible side effects of GEMTESA? 

GEMTESA may cause serious side effects, including the inability to empty your bladder (urinary  retention). GEMTESA may increase your chances of not being able to empty your bladder, especially if  you have bladder outlet obstruction or take other medicines for treatment of overactive bladder. Tell  your doctor right away if you are unable to empty your bladder. The most common side effects of  GEMTESA include headache, urinary tract infection, nasal congestion, sore throat or runny nose,  diarrhea, nausea, and upper respiratory tract infection. These are not all the possible side effects of  GEMTESA. For more information, ask your doctor or pharmacist. 

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA 1088. 

Please click here for full Product Information for GEMTESA. 

About Enzyvant Therapeutics  

Enzyvant is a biopharmaceutical company making life-altering impact for people affected by rare  disease, where the communities are small, and the human need is immense. Driven by purpose, we  engage with rare disease communities with compassion and commitment, partnering to accelerate the  development of transformative medicines they so urgently need. We prioritize collaborative  connections with academia, industry, associations, advocacy groups and government, because strong  relationships make bold science possible. A nimble and unique organization, Enzyvant has a full range of  capabilities spanning non-clinical and clinical development and commercialization and is developing in house manufacturing. Enzyvant has delivered a first-of-its-kind FDA approval in regenerative medicine  and promising advances against some of the greatest challenges in immunology and cardiopulmonology.  Enzyvant is part of Sumitovant, wholly owned by Sumitomo Pharma. For more information about  Enzyvant and our programs, visit

About Spirovant Sciences 

Spirovant is a gene therapy company focused on changing the course of cystic fibrosis and other  respiratory diseases. The company’s current investigational gene therapy technologies are designed to  overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis.  Spirovant’s lead programs are in development for cystic fibrosis. Spirovant, a wholly owned subsidiary of  Sumitovant Biopharma, is located in Philadelphia, PA. For more information, please visit our website at

About Sunovion Pharmaceuticals Inc.

Sunovion is a global biopharmaceutical company focused on the innovative application of science and  medicine to help people with serious medical conditions. Sunovion has charted new paths to life transforming treatments that reflect an ongoing commitment to research and development for people  living with serious psychiatric and neurological conditions. Headquartered in Marlborough, Mass.,  Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Pharma Co. Ltd. Sunovion  Pharmaceuticals Canada Inc., based in Mississauga, Ontario, is a wholly-owned direct subsidiary of  Sunovion Pharmaceuticals Inc. Additional information can be found on the company’s websites: and Connect with Sunovion on Twitter, LinkedIn, Facebook and  YouTube. 

About Sumitomo Pharma Oncology, Inc. 

Sumitomo Pharma Oncology, Inc. is a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. As a global  oncology organization with teams in the U.S. and Japan, SMP Oncology is committed to the goal of  advancing purposeful science by transforming new discoveries into meaningful treatments for patients  with cancer. SMP Oncology’s robust and diverse pipeline of preclinical and clinical-stage assets spans  multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions,  which aim to address unmet clinical needs in oncology. For more information, visit

About Sumitomo Pharma America Holdings, Inc. 

Sumitomo Pharma America Holdings, Inc. supports certain affiliates of the Sumitomo Pharma Group by  providing professional shared services expertise to achieve greater efficiencies and enable discovery,  development and commercialization of innovative treatments to help patients. Headquartered in  Marlborough, MA, U.S., Sumitomo Pharma America Holdings, Inc. is a wholly-owned subsidiary of  Sumitomo Pharma Co., Ltd., a global pharmaceutical company based in Japan.  

Forward Looking Statements 

This press release contains forward-looking statements that may be deemed to be “forward-looking  statements” within the meaning of applicable securities laws and Sumitomo Pharma may make related  oral, forward-looking statements on or following the date hereof. Statements including words such as  “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,”  “intend,” “guidance,” “future” or similar expressions are forward-looking statements. Forward-looking  statements, by their nature, are subject to a variety of inherent risks and uncertainties that could cause  actual results to differ materially from the results projected and reported results should not be  considered as an indication of future performance. Many of these risks and uncertainties cannot be  controlled by Sumitomo Pharma and you should not place undue reliance on any forward-looking  statements. These forward-looking statements are based on information available to Sumitomo Pharma  as of the date of this communication and speak only as of the date of this communication. Sumitomo  Pharma does not assume any obligation to publicly update any forward-looking statements, except as  may be required by law. No information contained on any website referenced in this press release is  incorporated by reference herein. 

Media / IR Contacts
Maya Frutiger
VP, Head of Corporate Communications

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>